Aminolevulinic acid dehydratase deficiency porphyria

Aminolevulinic acid dehydratase deficiency porphyria
Synonyms	Porphyria due to ALA dehydratase deficiency
Pronounce
Field
Symptoms
Complications
Onset
Duration
Types
Causes
Risks
Diagnosis
Differential diagnosis
Prevention
Treatment
Medication
Prognosis
Frequency
Deaths

Aminolevulinic acid dehydratase deficiency porphyria (also known as "Doss porphyria", "plumboporphyria", or "ADP") is a rare autosomal recessive metabolic disorder that results from inappropriately low levels of the enzyme delta-aminolevulinic acid dehydratase (ALAD), which is required for normal heme synthesis. This deficiency results in the accumulation of a toxic metabolic precursor in the heme synthesis pathway called aminolevulinic acid (ALA). Heme is a component of hemoglobin which carries oxygen in red blood cells.

ALA dehydratase deficiency is a rare cause of hepatic porphyria, meaning that excess porphyrins originate from the liver rather than the bone marrow as in erythropoietic porphyrias.

Signs and symptoms

The clinical presentation of ADP includes a wide range of neurologic and gastrointestinal symptoms. The severity of symptoms is dependent on how functional the ALAD enzyme is in each person. The higher the enzyme activity, the fewer symptoms a person will exhibit and the later they will present. The less functional a persons ALAD enzyme is, the earlier they will present and the more severe their symptoms will be.

The disease can present during early childhood (as well as in adulthood) with acute neurologic symptoms that resemble those encountered in acute intermittent porphyria. Patients can also have gastrointestinal symptoms during acute attacks, including abdominal cramping, vomiting, and constipation. Gastrointestinal symptoms can result in failure to thrive and poor weight gain in children. Other symptoms that can occur during an acute attack include a rapid heart beat, high blood pressure, and respiratory difficulties.

Acute attacks can last for weeks and are also called "neurovisceral" attacks due to the neurological complications associated. Patients have reported numbness and tingling in the extremities, seizures, burning pain, poor coordination, inability to move muscles voluntarily, and psychological disturbances. Psychosis, though rare, has occurred in severe instances.

Many triggers have been identified for acute ADP attacks including fasting, a low carb diet, dehydration, alcohol intake, the use of estrogen or progesterone, certain drugs, and other mental and physical stressors.

Genetics

ALA dehydratase deficiency is inherited in an autosomal recessive manner. This means a defective gene responsible for the disorder is located on an autosome, and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disorder.

In conditions where both parents are carriers:

• The risk of having a child with ADP is 25% for each pregnancy.
•  The risk of having a child who is also a carrier is 50%.
•  The chance of having a child who is unaffected and is not a carrier is 25%.

Diagnosis

To make a diagnosis, the relevant presenting symptoms and a detailed patient history must be considered in addition to obtaining biomarkers in the urine or blood. These biomarkers include urine porphobilinogen (PBG), aminolevulinic acid (ALA), and porphyrins found in blood and urine. PBG levels fluctuate and are best measured during the onset of acute symptoms. ALA levels are increased in ADP and correlate with the severity of the disease.

If levels of porphyrins are significantly elevated, DNA testing can be performed to determine the specific mutations in the ALAD gene. DNA analysis is the most specific test for making a diagnosis of ADP.

Treatment

Supportive care and treatment of symptoms are the typical management options for ADP. During acute attacks, patients are often hospitalized and given medications for nausea/vomiting, rapid heartbeat, and hypertension while their fluid and electrolyte levels are monitored. Glucose supplementation and intravenous hematin are the mainstay of treatment for acute attacks. Avoiding physical and psychological stressors has been shown to limit the reoccurrence of attacks.

Specific drugs have been identified that can trigger ADP attacks. Inducers of the CYP-450 enzymes are drugs that should be discontinued or avoided in patients with ADP. Drugs included in this category are anti-convulsants like phenytoin and carbamazepine, and other drugs like barbiturates, St. John's wort, and rifampin.

Prevalence

The condition is extremely rare, with fewer than 10 cases ever reported. All reported cases have been seen in males. A feature of ADP that separates it from other porphyrias is that it is more prevalent in males than in females. However, it theoretically affects males and females at the same rate. Most cases have been identified in Europe but it can occur in any population.

See also

• List of cutaneous conditions

External links

Classification	ICD-10: E80.2 OMIM: 612740
External resources	Orphanet: 100924